Evid Based Med doi:10.1136/ebm.2011.100057
  • Therapeutics
  • Systematic review and meta-analysis

High-dose statin before percutaneous coronary intervention lowers risk of periprocedural myocardial infarction and 30-day major cardiac adverse events

  1. Anthony A Bavry
  1. College of Medicine, Department of Medicine, University of Florida, Gainesville, Florida, USA
  1. Correspondence to: Anthony A Bavry
    College of Medicine, University of Florida, 1600 SW Archer Road, Gainesville, FL 32610, USA; bavryaa{at}

Commentary on:


In the current era, periprocedural myocardial infarction (MI) can still occur in a significant proportion of percutaneous coronary interventions (PCIs).1 Large periprocedural ischaemic events are associated with harm; however, even small increases in cardiac enzymes have been associated with increased long-term mortality.2 Attempts to enhance the safety of PCI have typically occurred through the use of potent antiplatelet agents (eg, aspirin, ADP receptor blockers (clopidogrel and prasugrel) and glycoprotein inhibitors (abciximab and eptifibatide)), as well as antithrombin agents (eg, unfractionated heparin, low-molecular weight heparin and bivalirudin). Although antiplatelet and antithrombin agents are effective at reducing ischaemic events, a cost from their use is sometimes paid in terms of major …

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBM.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article